Market Cap 121.01M
Revenue (ttm) 13.86M
Net Income (ttm) -79.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -574.46%
Debt to Equity Ratio 0.00
Volume 556,000
Avg Vol 476,282
Day's Range N/A - N/A
Shares Out 63.36M
Stochastic %K 12%
Beta 1.43
Analysts Strong Sell
Price Target $6.89

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monothera...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 453 3596
Address:
321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States
LabPsycho
LabPsycho May. 15 at 7:24 PM
$PYXS @Relee187200 IMO, on explanation might be market makers sucked out the quick money up 100% in weeks taking out their stop loss orders, then cueing up for the next pump before the money raise?
0 · Reply
Relee187200
Relee187200 May. 14 at 2:32 PM
$PYXS What the hell is going on??
1 · Reply
LabPsycho
LabPsycho May. 14 at 1:56 PM
$PYXS IMO, seems like they are running low on cash + the curiously timed $350M mixed shelf offering last November + the 100% gain in a few recent weeks suggests to me room to retrace further.
1 · Reply
focafoca99
focafoca99 May. 14 at 12:03 PM
$PYXS issued its Q1 2026 earnings, reporting results for the quarter ended March 31, 2026.
0 · Reply
StockScanners
StockScanners May. 9 at 4:04 PM
$PYXS keep watch if this holds above 2.43
0 · Reply
FonsieTrader
FonsieTrader May. 9 at 2:00 PM
$PYXS 👀 This one is trying to reclaim momentum after a brutal reset… and the chart is starting to wake up again. The Technicals: ✅ Strong bounce from the $1.20–1.30 zone ✅ Reclaiming key resistance around $2.15 ✅ TTM Squeeze momentum curling back up ✅ MFI pushing above 80 → aggressive money flow ✅ Volume expanding on breakout candles ✅ OBV stabilizing → selling pressure fading Key level now: $2.15 If bulls hold above that zone, this could quickly push toward the $3.80–5.00 range again. Biotech microcaps move FAST once momentum returns. This looks like the beginning of a new expansion phase.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES May. 8 at 2:20 PM
$PYXS I told u there it was going... This is what I do for my peeps in the Pitt 🌞 🌞 this was a freebie... Good luck 🫡
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES May. 8 at 1:47 PM
$PYXS Did u add with me??? Here comes $2.50... Another overnight swing winner.. We are on fire 🔥 🔥
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES May. 7 at 1:35 PM
$PYXS Adds! In the gap... $2.50 Or more no reason why not imo🚨🚨
0 · Reply
Ron_Burn
Ron_Burn May. 7 at 2:02 AM
$PYXS good performance today
0 · Reply
Latest News on PYXS
Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)

2026-05-14T13:11:04.000Z - 6 days ago

Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)


Pyxis Oncology Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 6 days ago

Pyxis Oncology Quarterly report: Q1 2026


Pyxis Oncology Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 6 days ago

Pyxis Oncology Earnings release: Q1 2026


Pyxis Oncology Slides: Investor presentation

May 13, 2026, 7:00 AM EDT - 7 days ago

Pyxis Oncology Slides: Investor presentation


Pyxis Oncology initiated with an Outperform at Wedbush

2026-05-05T11:30:55.000Z - 15 days ago

Pyxis Oncology initiated with an Outperform at Wedbush


Pyxis Oncology Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 20 days ago

Pyxis Oncology Proxy statement: Proxy filing


Pyxis Oncology Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 20 days ago

Pyxis Oncology Proxy statement: Proxy filing


Pyxis Oncology price target lowered to $8 from $9 at Stifel

2026-03-24T10:51:42.000Z - 2 months ago

Pyxis Oncology price target lowered to $8 from $9 at Stifel


Pyxis Oncology Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Pyxis Oncology Earnings release: Q4 2025


Pyxis Oncology Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Pyxis Oncology Annual report: Q4 2025


Pyxis Oncology Slides: Corporate presentation

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Pyxis Oncology Slides: Corporate presentation


Pyxis Oncology Transcript: Study Update

Dec 18, 2025, 8:30 AM EST - 5 months ago

Pyxis Oncology Transcript: Study Update


Pyxis Oncology Press release: Study Update

Dec 18, 2025, 8:30 AM EST - 5 months ago

Pyxis Oncology Press release: Study Update


Pyxis Oncology Slides: Study Update

Dec 18, 2025, 8:30 AM EST - 5 months ago

Pyxis Oncology Slides: Study Update


Pyxis Oncology sees cash runway into 4Q26

2025-12-18T12:17:22.000Z - 5 months ago

Pyxis Oncology sees cash runway into 4Q26


Pyxis Oncology files $350M mixed securities shelf

2025-11-26T14:15:39.000Z - 6 months ago

Pyxis Oncology files $350M mixed securities shelf


Pyxis Oncology Registration statement: Registration Filing

Nov 26, 2025, 7:00 AM EST - 6 months ago

Pyxis Oncology Registration statement: Registration Filing


Pyxis Oncology price target raised to $8 from $5 at Stephens

2025-11-24T12:35:39.000Z - 6 months ago

Pyxis Oncology price target raised to $8 from $5 at Stephens


Pyxis Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 4:00 PM EST - 6 months ago

Pyxis Oncology Transcript: Stifel 2025 Healthcare Conference


Pyxis Oncology Quarterly report: Q3 2025

Nov 3, 2025, 4:00 PM EST - 7 months ago

Pyxis Oncology Quarterly report: Q3 2025


Pyxis Oncology reports Q3 EPS (35c), consensus (34c)

2025-11-03T12:12:11.000Z - 7 months ago

Pyxis Oncology reports Q3 EPS (35c), consensus (34c)


Pyxis Oncology resumed with a Buy at Stifel

2025-11-03T11:51:01.000Z - 7 months ago

Pyxis Oncology resumed with a Buy at Stifel


Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets

2025-10-09T11:35:39.000Z - 7 months ago

Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets


Pyxis Oncology initiated with a Buy at Guggenheim

2025-09-04T09:40:07.000Z - 9 months ago

Pyxis Oncology initiated with a Buy at Guggenheim


Pyxis Oncology initiated with a Buy at Guggenheim

2025-09-03T20:31:05.000Z - 9 months ago

Pyxis Oncology initiated with a Buy at Guggenheim


Pyxis Oncology reports Q2 EPS (30c), consensus (35c)

2025-08-14T20:15:50.000Z - 9 months ago

Pyxis Oncology reports Q2 EPS (30c), consensus (35c)


Pyxis Oncology Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 9 months ago

Pyxis Oncology Earnings release: Q2 2025


Pyxis Oncology Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 9 months ago

Pyxis Oncology Quarterly report: Q2 2025


Crescent Biopharma appoints Jan Pinkas as CSO

2025-07-08T11:36:10.000Z - 11 months ago

Crescent Biopharma appoints Jan Pinkas as CSO

CBIO


Pyxis Oncology Slides: Corporate Presentation

May 16, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Slides: Corporate Presentation


Pyxis Oncology Earnings release: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Pyxis Oncology Earnings release: Q1 2025


Pyxis Oncology Quarterly report: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Pyxis Oncology Quarterly report: Q1 2025


Pyxis Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Annual report: Q4 2024


Pyxis Oncology Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Earnings release: Q4 2024


Pyxis Oncology Transcript: Status Update

Nov 20, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology Transcript: Status Update


Pyxis Oncology Slides: Status Update

Nov 20, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology Slides: Status Update


Pyxis Oncology Quarterly report: Q3 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Pyxis Oncology Quarterly report: Q3 2024


Pyxis Oncology Proxy statement: Proxy Filing

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Proxy statement: Proxy Filing

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Quarterly report: Q2 2024


Pyxis Oncology Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Earnings release: Q2 2024


Pyxis Oncology Slides: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Slides: Q2 2024


Pyxis Oncology Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Pyxis Oncology Quarterly report: Q1 2024


Pyxis Oncology Earnings release: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Pyxis Oncology Earnings release: Q1 2024


Pyxis Oncology Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Registration statement: Registration Filing

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Registration statement: Registration Filing


Pyxis Oncology Annual report: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pyxis Oncology Annual report: Q4 2023


Pyxis Oncology Earnings release: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pyxis Oncology Earnings release: Q4 2023


Pyxis Oncology Slides: Corporate Presentation

Dec 19, 2023, 12:50 PM EST - 2 years ago

Pyxis Oncology Slides: Corporate Presentation


Pyxis Oncology Quarterly report: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Pyxis Oncology Quarterly report: Q3 2023


Pyxis Oncology Earnings release: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Pyxis Oncology Earnings release: Q3 2023


Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 23, 2023, 8:35 AM EDT - 2 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen


Pyxis Oncology Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Quarterly report: Q2 2023


Pyxis Oncology Earnings release: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Earnings release: Q2 2023


Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 30, 2023, 8:30 AM EDT - 3 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs


Pyxis Oncology Transcript: M&A Announcement

May 24, 2023, 7:01 AM EDT - 3 years ago

Pyxis Oncology Transcript: M&A Announcement


Pyxis Oncology Press release: M&A Announcement

May 24, 2023, 7:01 AM EDT - 3 years ago

Pyxis Oncology Press release: M&A Announcement


Pyxis Oncology Slides: M&A Announcement

May 24, 2023, 7:01 AM EDT - 3 years ago

Pyxis Oncology Slides: M&A Announcement


Pyxis Oncology to Acquire Apexigen

May 24, 2023, 6:45 AM EDT - 3 years ago

Pyxis Oncology to Acquire Apexigen


Pyxis Oncology Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Pyxis Oncology Proxy statement: Proxy Filing


Pyxis Oncology Annual report: Q4 2022

Mar 22, 2023, 6:46 AM EDT - 3 years ago

Pyxis Oncology Annual report: Q4 2022


LabPsycho
LabPsycho May. 15 at 7:24 PM
$PYXS @Relee187200 IMO, on explanation might be market makers sucked out the quick money up 100% in weeks taking out their stop loss orders, then cueing up for the next pump before the money raise?
0 · Reply
Relee187200
Relee187200 May. 14 at 2:32 PM
$PYXS What the hell is going on??
1 · Reply
LabPsycho
LabPsycho May. 14 at 1:56 PM
$PYXS IMO, seems like they are running low on cash + the curiously timed $350M mixed shelf offering last November + the 100% gain in a few recent weeks suggests to me room to retrace further.
1 · Reply
focafoca99
focafoca99 May. 14 at 12:03 PM
$PYXS issued its Q1 2026 earnings, reporting results for the quarter ended March 31, 2026.
0 · Reply
StockScanners
StockScanners May. 9 at 4:04 PM
$PYXS keep watch if this holds above 2.43
0 · Reply
FonsieTrader
FonsieTrader May. 9 at 2:00 PM
$PYXS 👀 This one is trying to reclaim momentum after a brutal reset… and the chart is starting to wake up again. The Technicals: ✅ Strong bounce from the $1.20–1.30 zone ✅ Reclaiming key resistance around $2.15 ✅ TTM Squeeze momentum curling back up ✅ MFI pushing above 80 → aggressive money flow ✅ Volume expanding on breakout candles ✅ OBV stabilizing → selling pressure fading Key level now: $2.15 If bulls hold above that zone, this could quickly push toward the $3.80–5.00 range again. Biotech microcaps move FAST once momentum returns. This looks like the beginning of a new expansion phase.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES May. 8 at 2:20 PM
$PYXS I told u there it was going... This is what I do for my peeps in the Pitt 🌞 🌞 this was a freebie... Good luck 🫡
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES May. 8 at 1:47 PM
$PYXS Did u add with me??? Here comes $2.50... Another overnight swing winner.. We are on fire 🔥 🔥
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES May. 7 at 1:35 PM
$PYXS Adds! In the gap... $2.50 Or more no reason why not imo🚨🚨
0 · Reply
Ron_Burn
Ron_Burn May. 7 at 2:02 AM
$PYXS good performance today
0 · Reply
StockScanners
StockScanners May. 7 at 12:33 AM
$PYXS keep watch if this holds above 2.21
0 · Reply
ElectricEel86
ElectricEel86 May. 6 at 9:35 PM
$PYXS wow!! Def bullish
0 · Reply
topstockalerts
topstockalerts May. 6 at 8:02 PM
$PYXS been waiting for this one to move… finally happening
0 · Reply
Youngmoney22choppa
Youngmoney22choppa May. 6 at 7:33 PM
0 · Reply
MadMaverick
MadMaverick May. 6 at 7:24 PM
🚨$GANX - Parkinson's drug GT-02287 just wrapped Phase 1b. Here's what the data shows: 21 patients enrolled. 19 completed 90 days. 84% of eligible patients voluntarily chose to continue into the 9-month extension. You don't stay in a trial if it's not working. ✅Extension ongoing until Q3 2026 → 16 patients. Results coming. ✅Safety, tolerability + biomarker signal in Parkinson's patients with or without GBA1 mutation. ✅First-in-human already confirmed GCase target engagement. Phase 2 launch targeted Q3 2026. 4 analysts. All Strong Buy. $7.50 price target. The extension retention rate tells the story. Communicated Disclaimer - DYOR too. https://chartingdaily.com/structural-health Other biotech stocks running up today: $PYXS $AVTX $ERNA
2 · Reply
OriginalTradeonrumor
OriginalTradeonrumor May. 6 at 7:21 PM
$PYXS sold half my holdings at 2.35…great move!!!!
1 · Reply
LabPsycho
LabPsycho May. 6 at 6:07 PM
$PYXS Like I posted below.....right on target
0 · Reply
notreload_ai
notreload_ai May. 5 at 4:54 PM
Wedbush rates $PYXS “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs. https://notreload.xyz/xy/wedbush-bullish-on-pyxis-oncology-215-upside-ahead/
0 · Reply
DARKP00L
DARKP00L May. 5 at 1:31 PM
$PYXS 09:26 on May. 05 2026 Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6 #tradeideas
0 · Reply
Youngmoney22choppa
Youngmoney22choppa May. 5 at 12:55 PM
$PYXS Stifle knows what they are talking about
0 · Reply
FUNKDCTR
FUNKDCTR May. 4 at 2:26 PM
$PYXS it's good
1 · Reply
ElectricEel86
ElectricEel86 May. 1 at 7:43 PM
0 · Reply